Treatment of acute pulmonary embolism with dabigatran versus warfarin

<p>Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Goldhaber, Samuel Zachary (VerfasserIn) , Feuring, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016
In: Thrombosis and haemostasis
Year: 2017, Jahrgang: 116, Heft: 10, Pages: 714-721
ISSN:2567-689X
DOI:10.1160/TH16-04-0271
Online-Zugang:Verlag, Volltext: https://doi.org/10.1160/TH16-04-0271
Verlag: http://www.thieme-connect.de/DOI/DOI?10.1160/TH16-04-0271
Volltext
Verfasserangaben:Samuel Z. Goldhaber, Sebastian Schellong, Ajay Kakkar, Henry Eriksson, Martin Feuring, Joerg Kreuzer, Mandy Fraessdorf, Sam Schulman

MARC

LEADER 00000caa a2200000 c 4500
001 1684169194
003 DE-627
005 20220817174142.0
007 cr uuu---uuuuu
008 191204r20162017xx |||||o 00| ||eng c
024 7 |a 10.1160/TH16-04-0271  |2 doi 
035 |a (DE-627)1684169194 
035 |a (DE-599)KXP1684169194 
035 |a (OCoLC)1341280450 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Goldhaber, Samuel Zachary  |e VerfasserIn  |0 (DE-588)117136735X  |0 (DE-627)1040515673  |0 (DE-576)513719261  |4 aut 
245 1 0 |a Treatment of acute pulmonary embolism with dabigatran versus warfarin  |c Samuel Z. Goldhaber, Sebastian Schellong, Ajay Kakkar, Henry Eriksson, Martin Feuring, Joerg Kreuzer, Mandy Fraessdorf, Sam Schulman 
264 1 |c 2016 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.12.2019 
500 |a Publikationsdatum: 02. Dezember 2017 
520 |a <p>Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset for the efficacy analysis consisted of 2553 and 2554 patients who were randomised to dabigatran and warfarin, respectively. Recurrent VTE/VTE-related death during the study period and additional 30-day follow-up occurred in 2.7 % of all patients on dabigatran and in 2.4 % on warfarin (hazard ratio [HR] 1.09 [95 % confidence interval 0.77, 1.54]). In patients with PE as their index event, recurrent VTE/VTE-related death occurred in 2.9 % vs 3.1 % of patients (HR 0.93 [0.53, 1.64]). There were significantly fewer major bleeding events in patients treated with dabigatran than with warfarin (HR 0.60 [0.36, 0.99]). The pattern was similar both in patients with PE and in those with DVT alone as the index event. These analyses of the pooled dataset from the RECOVER and RE-COVER II trials indicate that dabigatran is as effective as warfarin in preventing recurrent VTE, regardless of whether patients present with symptomatic PE (with or without DVT) or with symptomatic DVT alone. Dabigatran was also associated with a lower risk of bleeding than warfarin, regardless of the index event.</p> 
534 |c 2017 
700 1 |a Feuring, Martin  |d 1963-2018  |e VerfasserIn  |0 (DE-588)1075744083  |0 (DE-627)833665383  |0 (DE-576)176498125  |4 aut 
773 0 8 |i Enthalten in  |t Thrombosis and haemostasis  |d Stuttgart : Thieme, 1976  |g 116(2016), 10, Seite 714-721  |h Online-Ressource  |w (DE-627)302723188  |w (DE-600)1492370-1  |w (DE-576)079877362  |x 2567-689X  |7 nnas  |a Treatment of acute pulmonary embolism with dabigatran versus warfarin 
773 1 8 |g volume:116  |g year:2016  |g number:10  |g pages:714-721  |g extent:8  |a Treatment of acute pulmonary embolism with dabigatran versus warfarin 
856 4 0 |u https://doi.org/10.1160/TH16-04-0271  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.thieme-connect.de/DOI/DOI?10.1160/TH16-04-0271  |x Verlag 
951 |a AR 
992 |a 20191204 
993 |a Article 
994 |a 2016 
998 |g 1075744083  |a Feuring, Martin  |m 1075744083:Feuring, Martin  |d 60000  |e 60000PF1075744083  |k 0/60000/  |p 5 
999 |a KXP-PPN1684169194  |e 3556347660 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"8 S."}],"relHost":[{"title":[{"subtitle":"journal of the International Society on Thrombosis and Haemostasis","title":"Thrombosis and haemostasis","title_sort":"Thrombosis and haemostasis"}],"recId":"302723188","language":["eng"],"note":["Gesehen am 15.06.2018"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Treatment of acute pulmonary embolism with dabigatran versus warfarinThrombosis and haemostasis","part":{"extent":"8","volume":"116","text":"116(2016), 10, Seite 714-721","issue":"10","pages":"714-721","year":"2016"},"pubHistory":["35.1976 -"],"id":{"issn":["2567-689X"],"zdb":["1492370-1"],"doi":["10.1055/s-00035024"],"eki":["302723188"]},"origin":[{"publisherPlace":"Stuttgart ; Stuttgart","dateIssuedKey":"1976","publisher":"Thieme ; Schattauer","dateIssuedDisp":"1976-"}],"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"id":{"eki":["1684169194"],"doi":["10.1160/TH16-04-0271"]},"name":{"displayForm":["Samuel Z. Goldhaber, Sebastian Schellong, Ajay Kakkar, Henry Eriksson, Martin Feuring, Joerg Kreuzer, Mandy Fraessdorf, Sam Schulman"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 04.12.2019","Publikationsdatum: 02. Dezember 2017"],"recId":"1684169194","language":["eng"],"title":[{"title_sort":"Treatment of acute pulmonary embolism with dabigatran versus warfarin","title":"Treatment of acute pulmonary embolism with dabigatran versus warfarin"}],"person":[{"given":"Samuel Zachary","family":"Goldhaber","role":"aut","display":"Goldhaber, Samuel Zachary","roleDisplay":"VerfasserIn"},{"display":"Feuring, Martin","roleDisplay":"VerfasserIn","role":"aut","family":"Feuring","given":"Martin"}]} 
SRT |a GOLDHABERSTREATMENTO2016